Chasing Astellas and Mitsubishi, GSK files for Japanese approval of oral anemia drug

GlaxoSmithKline has filed for approval of renal anemia drug daprodustat in Japan. The filing follows data from Japanese phase 3 trials that assessed the oral hypoxia-inducible factor prolyl hydroxylase inhibitor in chronic kidney disease patients.